Vincristine impedes NSCLC progression by disrupting cell-cycle dynamics and inducing apoptosis (AbouEl et al., 2006; Ahn et al., 2013; Proia et al., 2012), whereas tenacissoside inhibits gefitinib metabolites (M523595, M608236, and M537194) within 24 h post-administration and suppresses hepatic CYP2D6/CYP3A4 activity within 6 h (Zhao et al., 2020). This evidence concerns the gene CYP3A4 and non-small cell lung carcinoma.